Among patients with substance use disorders (SUD), adult attention deficit hyperactivity
disorder (ADHD) is one of the most frequently co-occuring disorder. Those SUD patients
with comorbid ADHD show earlier onset of substance use, more severe SUD and poor treatment
outcomes. Therefore, early recognition of ADHD is highly rele - vant within this patient
population. The results of available screening instruments may lay the foundation
of timely ADHD diagnosis. Considering the integrated treatment of patients with a
dual ADHD+SUD diagnosis, the applica tion of combined pharmaco- and psychotherapy
is recommended. Based on the evidence-and consensus-based suggestions, prescription
of long-acting methylphenidate, extended-release amphetamines and atomoxetine with
up-titration might be the best choice in the treatment of patients who are either
unresponsive to standard dose or characterized by therapy resistance. The main purpose
of this manuscript is to establish a standing-ground for the effective screening,
diagnosis and treatment of ADHD+SUD patients.
